Get the Stockscreener App
4.15
3.26%
-0.14
Polypid Ltd stock is traded at $4.15, with a volume of 38,614.
It is down -3.26% in the last 24 hours and down -8.79% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$4.29
Open:
$4.25
24h Volume:
38,614
Relative Volume:
0.53
Market Cap:
$76.18M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.211
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
-2.81%
1M Performance:
-8.79%
6M Performance:
+21.35%
1Y Performance:
+33.87%
1-Day Range:
$4.15
$4.27
1-Week Range:
$4.15
$4.3789
52-Week Range:
$2.30
$5.12
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.185 | 78.10M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.75 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
757.41 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
768.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.73 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.27 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
Biotech PolyPid sets March investor chats in Miami and Dana Point - Stock Titan
Is PolyPid Ltd. stock forming a triangle patternJuly 2025 Recap & Daily Profit Maximizing Trade Tips - mfd.ru
Does PolyPid Ltd. have high return on assetsMarket Sentiment Report & Long-Term Growth Portfolio Plans - mfd.ru
Is PolyPid Ltd. stock technically oversoldJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - mfd.ru
Polypid targets rolling NDA submission for D-PLEX100 by end of Q1 2026 amid advanced US partnership talks - MSN
Aug Decliners: Is PolyPid Ltd likely to announce a buyback2025 Technical Patterns & Fast Gain Swing Trade Alerts - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 44.8% in January - MarketBeat
Research Analysts Issue Forecasts for PolyPid Q1 Earnings - Defense World
HC Wainwright Predicts PolyPid's Q1 Earnings (NASDAQ:PYPD) - MarketBeat
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit? - Yahoo Finance
PolyPid Q4 Earnings Call Highlights - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 Earnings Call Transcript - Insider Monkey
Is PolyPid Ltd. likely to announce a buybackJuly 2025 Recap & Low Risk High Win Rate Picks - mfd.ru
FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright - MarketBeat
PolyPid Earnings Call Flags Big 2026 Catalyst - TipRanks
PolyPid (PYPD) Analyst Rating Reiteration by HC Wainwright | PYP - GuruFocus
PolyPid (NASDAQ:PYPD) Earns Buy Rating from HC Wainwright - MarketBeat
PolyPid (NASDAQ:PYPD) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Earnings call transcript: PolyPid’s Q4 2025 results miss EPS forecasts By Investing.com - Investing.com Australia
Earnings call transcript: PolyPid’s Q4 2025 results miss EPS forecasts - Investing.com India
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
PolyPid Ltd. Advances U.S. Partnership Talks for D-PLEX₁₀₀ Following Positive FDA Feedback and Plans Rolling NDA Review - Quiver Quantitative
Preview: PolyPid's Earnings - Benzinga
Will PolyPid Ltd. stock recover after earnings2025 AllTime Highs & Capital Protection Trade Alerts - mfd.ru
Aug Closing: Is PolyPid Ltd likely to announce a buybackMarket Activity Summary & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
PolyPid Ltd. (NASDAQ:PYPD) Sees Large Decrease in Short Interest - MarketBeat
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 - The Manila Times
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will PolyPid Gain Momentum Ahead Of Its NDA Filing? - RTTNews
Rate Hike: Will VF Corporation announce a stock splitWeekly Trade Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Aug Movers: Is AAME forming bullish engulfing patternsEarnings Trend Report & Consistent Profit Alerts - baoquankhu1.vn
Guidance Update: Should I set a stop loss on Co Diagnostics IncPortfolio Gains Report & Safe Entry Trade Signal Reports - baoquankhu1.vn
PolyPid calls February 2026 extraordinary meeting to approve board chair compensation - MSN
Aug Sentiment: Is PolyPid Ltd stock technically oversoldJuly 2025 Institutional & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
PYPD: D-PLEX 100's phase 3 success paves the way for FDA submission and U.S. commercialization - TradingView
Aug Catalysts: Will PolyPid Ltd stock return to pre crisis levels2025 Buyback Activity & Low Risk High Win Rate Picks - Bộ Nội Vụ
Why analysts remain bullish on PolyPid Ltd. stockQuarterly Risk Review & High Conviction Buy Zone Alerts - Улправда
Aug Big Picture: Can PolyPid Ltd. stock hit analyst price targetsJuly 2025 Earnings & Intraday High Probability Setup Alerts - Улправда
Will PolyPid Ltd. stock keep outperforming rivals2026 world cup usa national team group stage young talents high defensive line odds analysis expert opinion - ulpravda.ru
PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Moves: Can PolyPid Ltd stock sustain free cash flow growthForecast Cut & Accurate Entry/Exit Alerts - moha.gov.vn
Contrasting PolyPid (NASDAQ:PYPD) & Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation - TipRanks
PolyPid files for secondary offering - MSN
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December - MarketBeat
Value Recap: Will PolyPid Ltd. stock keep outperforming rivals2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Will PolyPid Ltd. stock outperform international peersMarket Growth Review & Real-Time Volume Analysis Alerts - Улправда
Can PolyPid Ltd. stock sustain free cash flow growthQuarterly Growth Report & Step-by-Step Trade Execution Guides - DonanımHaber
Why PolyPid Ltd. stock attracts global investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):